96 related articles for article (PubMed ID: 6196407)
1. Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant.
Taketani S; Krangel MS; Pious D; Strominger JL
J Immunol; 1983 Dec; 131(6):2935-8. PubMed ID: 6196407
[TBL] [Abstract][Full Text] [Related]
2. Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes. II. Variant DK1: evidence for a discrete CTL recognition region.
Krangel MS; Biddison WE; Strominger JL
J Immunol; 1983 Apr; 130(4):1856-62. PubMed ID: 6601143
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant.
Krangel MS; Taketani S; Pious D; Strominger JL
J Exp Med; 1983 Jan; 157(1):324-36. PubMed ID: 6184441
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a B lymphoblastoid cell line mutant that secretes HLA-A2.
Krangel MS; Pious D; Strominger JL
J Immunol; 1984 Jun; 132(6):2984-91. PubMed ID: 6609965
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of an HLA-B7 antigen variant detected by cytotoxic T lymphocytes.
Taketani S; Krangel MS; Spits H; de Vries J; Strominger JL
J Immunol; 1984 Aug; 133(2):816-21. PubMed ID: 6429245
[TBL] [Abstract][Full Text] [Related]
6. Amino acid residues 56 to 69 of HLA-A2 specify an antigenic determinant shared by HLA-A2 and HLA-B17.
Ways JP; Rothbard JB; Parham P
J Immunol; 1986 Jul; 137(1):217-22. PubMed ID: 2423602
[TBL] [Abstract][Full Text] [Related]
7. Creation of an HLA-A2/HLA-Aw69 alloantigenic determinant on an HLA-A3 molecule by site-directed mutagenesis.
Layet C; Kahn-Perles B; Pontarotti P; Ferrier P; Sire J; Lemonnier FA
J Immunol; 1987 Apr; 138(7):2197-201. PubMed ID: 2435791
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule.
Santos-Aguado J; Barbosa JA; Biro PA; Strominger JL
J Immunol; 1988 Oct; 141(8):2811-8. PubMed ID: 2459229
[TBL] [Abstract][Full Text] [Related]
9. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
Slingluff CL; Cox AL; Henderson RA; Hunt DF; Engelhard VH
J Immunol; 1993 Apr; 150(7):2955-63. PubMed ID: 7681084
[TBL] [Abstract][Full Text] [Related]
10. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
11. Delineation of immunologically and biochemically distinct HLA-A2 antigens.
Biddison WE; Kostyu DD; Strominger JL; Krangel MS
J Immunol; 1982 Aug; 129(2):730-4. PubMed ID: 6177780
[TBL] [Abstract][Full Text] [Related]
12. Hybrid genes between HLA-A2 and HLA-A3 constructed by in vivo recombination allow mapping of HLA-A2 and HLA-A3 polymorphic antigenic determinants.
Sire J; Chimini G; Boretto J; Toubert A; Kahn-Perles B; Layet C; Sodoyer R; Lemonnier F; Jordan B
J Immunol; 1988 Apr; 140(7):2422-30. PubMed ID: 2450922
[TBL] [Abstract][Full Text] [Related]
13. Human histocompatibility antigen mutants immunoselected in vitro. Biochemical analysis of a mutant which synthesizes an altered HLA-A2 heavy chain.
Krangel MS; Pious D; Strominger JL
J Biol Chem; 1982 May; 257(9):5296-305. PubMed ID: 6978338
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR antigens have polymorphic light chains and invariant heavy chains as assessed by lysine-containing tryptic peptide analysis.
Kaufman JF; Andersen RL; Strominger JL
J Exp Med; 1980 Aug; 152(2 Pt 2):37s-53s. PubMed ID: 6774044
[TBL] [Abstract][Full Text] [Related]
15. Public epitopes and the antigenic structure of the HLA molecules.
Rodey GE; Fuller TC
Crit Rev Immunol; 1987; 7(3):229-67. PubMed ID: 2441930
[TBL] [Abstract][Full Text] [Related]
16. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
18. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.
Jansen CA; Kostense S; Vandenberghe K; Nanlohy NM; De Cuyper IM; Piriou E; Manting EH; Miedema F; van Baarle D
Eur J Immunol; 2005 Jan; 35(1):150-8. PubMed ID: 15593302
[TBL] [Abstract][Full Text] [Related]
19. HLA-DR antigens of autologous melanoma and B lymphoblastoid cell lines: differences in glycosylation but not protein structure.
Alexander S; Hubbard SC; Strominger JL
J Immunol; 1984 Jul; 133(1):315-20. PubMed ID: 6609984
[TBL] [Abstract][Full Text] [Related]
20. The antigenic structure of HLA-A2: an analysis with competitive binding assays and monoclonal antibodies.
Ways JP; Parham P
J Immunol; 1983 Aug; 131(2):856-63. PubMed ID: 6190942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
